

Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease

Neurology[®] 2019;00:1. doi:10.1212/WNL.0000000000008908

In the article “Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease” by Feustel et al.,¹ first published online December 2, 2019, the first label under the “Parkinson disease” heading in figure 4 should read “e-Ref #36” and the second label should read “e-Ref #37.” The labels appear correctly in the January 7, 2020, issue. The publisher regrets the errors.

Reference

1. Feustel AC, MacPherson A, Fergusson DA, Kieburtz K, Kimmelman J. Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease. *Neurology* 2020;94:e1–e14.

Neurology®

Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease

Neurology published online September 16, 2020
DOI 10.1212/WNL.0000000000008908

This information is current as of September 16, 2020

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/early/2020/09/16/WNL.0000000000008908.citation.full
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2020 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

